Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Br J Haematol. 2020 Mar 2;190(3):405–417. doi: 10.1111/bjh.16530

Figure 4: ABC294640 induces selective apoptosis in PBMCs from LGL leukemia patients.

Figure 4:

A) PBMC samples from LGL leukemia patients or PBMC samples from normal donors were treated with DMSO or ABC294640 at the indicated doses for 48 hours and assayed for apoptosis B) and C) ABC294640 induces dose-dependent apoptosis in representative T-LGL (#1866) or NK-LGL (#2012) patients. *, p < 0.05, indicate significant differences of ABC294640 of T-LGL versus normal PBMCs (Student’s t-test) or ABC294640-treated versus vehicle control (DMSO) treated cells for all doses (one-way ANOVA).